PT1392307E - Sais tartarato de 5,8,14-triazatetraciclo-[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno - Google Patents

Sais tartarato de 5,8,14-triazatetraciclo-[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno

Info

Publication number
PT1392307E
PT1392307E PT02722625T PT02722625T PT1392307E PT 1392307 E PT1392307 E PT 1392307E PT 02722625 T PT02722625 T PT 02722625T PT 02722625 T PT02722625 T PT 02722625T PT 1392307 E PT1392307 E PT 1392307E
Authority
PT
Portugal
Prior art keywords
triazatetracyclo
pentaene
hexadeca
salts
Prior art date
Application number
PT02722625T
Other languages
English (en)
Inventor
Bogle David Everett
Rose Peter Robert
Williams Glenn Robert
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23117845&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1392307(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PT1392307E publication Critical patent/PT1392307E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
PT02722625T 2001-05-14 2002-04-26 Sais tartarato de 5,8,14-triazatetraciclo-[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno PT1392307E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29086101P 2001-05-14 2001-05-14

Publications (1)

Publication Number Publication Date
PT1392307E true PT1392307E (pt) 2005-11-30

Family

ID=23117845

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02722625T PT1392307E (pt) 2001-05-14 2002-04-26 Sais tartarato de 5,8,14-triazatetraciclo-[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno

Country Status (48)

Country Link
US (2) US6890927B2 (pt)
EP (1) EP1392307B1 (pt)
JP (1) JP3779682B2 (pt)
KR (1) KR100551184B1 (pt)
CN (1) CN100370987C (pt)
AP (1) AP1473A (pt)
AR (1) AR033635A1 (pt)
AT (1) ATE302607T1 (pt)
AU (1) AU2002253482B2 (pt)
BG (1) BG66408B1 (pt)
BR (1) BR0209605A (pt)
CA (1) CA2447405C (pt)
CR (1) CR7080A (pt)
CZ (1) CZ304763B6 (pt)
DE (1) DE60205742T2 (pt)
DK (1) DK1392307T3 (pt)
DO (1) DOP2002000392A (pt)
EA (1) EA005528B1 (pt)
EC (2) ECSP034849A (pt)
EE (1) EE05441B1 (pt)
EG (1) EG24228A (pt)
ES (1) ES2246396T3 (pt)
GE (1) GEP20053712B (pt)
GT (1) GT200200084A (pt)
HK (1) HK1062645A1 (pt)
HR (1) HRP20030910B1 (pt)
HU (1) HU229867B1 (pt)
IL (2) IL157933A0 (pt)
IS (1) IS2217B (pt)
MA (1) MA27020A1 (pt)
ME (1) ME00466B (pt)
MX (1) MXPA03010364A (pt)
MY (1) MY127807A (pt)
NO (1) NO326148B1 (pt)
NZ (1) NZ528210A (pt)
OA (1) OA12599A (pt)
PA (1) PA8545101A1 (pt)
PE (1) PE20021065A1 (pt)
PL (1) PL214876B1 (pt)
PT (1) PT1392307E (pt)
RS (1) RS50814B (pt)
SI (1) SI1392307T1 (pt)
SK (1) SK287170B6 (pt)
TN (1) TNSN03113A1 (pt)
TW (1) TWI262078B (pt)
UA (1) UA73422C2 (pt)
WO (1) WO2002092089A1 (pt)
ZA (1) ZA200307235B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1715280A (zh) * 1997-12-31 2006-01-04 辉瑞产品公司 芳基稠合氮杂多环化合物
PL208080B1 (pl) * 2001-11-30 2011-03-31 Pfizer Prod Inc Postacie dawkowane zawierające 5,8,14-triazatetracyklo[10.3.1.0²’¹¹.0⁴’⁹]heksadeka-2(11),3,5,7,9-pentaen i zastosowanie 5,8,14-triazatetracyklo[10.3.1.0²’¹¹.0⁴’⁹] heksadeka-2(11),3,5,7,9-pentaenu
CA2525874C (en) * 2003-05-20 2007-11-27 Pfizer Products Inc. Pharmaceutical compositions of varenicline
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2005105788A1 (en) * 2004-04-23 2005-11-10 Takeda San Diego, Inc. Indole derivatives and use thereof as kinase inhibitors
BRPI0512245A (pt) * 2004-06-30 2008-02-19 Lilly Co Eli composto, composição farmacêutica, e, uso do composto
WO2006023931A2 (en) * 2004-08-18 2006-03-02 Takeda San Diego, Inc. Kinase inhibitors
US7713973B2 (en) 2004-10-15 2010-05-11 Takeda Pharmaceutical Company Limited Kinase inhibitors
JP2008516942A (ja) * 2004-10-15 2008-05-22 ファイザー・プロダクツ・インク バレニクリンの鼻腔内、バッカル、舌下および肺送達のための組成物および方法
KR20070098942A (ko) * 2005-02-24 2007-10-05 화이자 프로덕츠 인코포레이티드 고순도의 치환된 퀴녹살린의 제조 방법
US20110086086A1 (en) * 2005-07-26 2011-04-14 Pfizer Inc Transdermal system for varenicline
US8119655B2 (en) * 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007098273A2 (en) * 2006-02-21 2007-08-30 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of armodafinil and preparation thereof
JP2010505961A (ja) * 2006-10-09 2010-02-25 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
GEP20135728B (en) 2006-10-09 2013-01-25 Takeda Pharmaceuticals Co Kinase inhibitors
WO2008060487A2 (en) * 2006-11-09 2008-05-22 Pfizer Products Inc. Polymorphs of nicotinic intermediates
US20090062257A1 (en) * 2007-08-29 2009-03-05 Protia, Llc Deuterium-enriched varenicline
WO2009045488A2 (en) * 2007-10-02 2009-04-09 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of armodafinil and preparation thereof
US20090215787A1 (en) * 2008-02-22 2009-08-27 Mai De Ltd. Preparations of new polymorphic forms of varenicline tartrate
US8440825B2 (en) 2008-03-06 2013-05-14 Medichem S.A. Fumaric acid salt of varenicline
WO2009111623A2 (en) * 2008-03-06 2009-09-11 Dr. Reddy's Laboratories Ltd. Amorphous varenicline tartrate
WO2009146031A1 (en) 2008-03-31 2009-12-03 University Of South Florida Methods of treating disease-induced ataxia and non-ataxic imbalance
CA2709774C (en) 2008-05-22 2012-10-02 Teva Pharmaceutical Industries Ltd. Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate
US20090318460A1 (en) * 2008-05-26 2009-12-24 Glenmark Amorphous varenicline tartrate and process for the preparation thereof
WO2009155403A2 (en) * 2008-06-19 2009-12-23 Teva Pharmaceutical Industries Ltd. Processes for the preparation of varenicline and intermediates thereof
WO2010005643A1 (en) * 2008-07-10 2010-01-14 Teva Pharmaceutical Industries Ltd. Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt
EP2334679A1 (en) * 2008-09-01 2011-06-22 Actavis Group PTC EHF Process for preparing varenicline, varenicline intermediates, and pharmaceutically acceptable salts thereof
EP2440187A2 (en) 2009-06-10 2012-04-18 Actavis Group PTC ehf. Amorphous varenicline tartrate co-precipitates
US8178537B2 (en) 2009-06-22 2012-05-15 Teva Pharmaceutical Industries Ltd. Solid state forms of varenicline salts and processes for preparation thereof
EP2545054A1 (en) 2010-03-09 2013-01-16 Actavis Group Ptc Ehf Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity
WO2011140431A1 (en) 2010-05-06 2011-11-10 Teva Pharmaceutical Industries Ltd. Varenicline salts and crystal forms thereof
CN104334561B (zh) 2012-04-13 2016-06-22 连云港金康和信药业有限公司 化合物jk12a及其制备
KR101663550B1 (ko) * 2014-06-11 2016-10-07 조선대학교산학협력단 주석산을 유효성분으로 포함하는 고혈압 예방 또는 치료용 약학조성물 및 건강기능식품
KR101724301B1 (ko) 2016-11-22 2017-04-10 주식회사 한서켐 바레니클린 살리실산염의 i형 결정 및 그 제조방법
WO2018154395A2 (en) 2018-06-11 2018-08-30 Alvogen Malta Operations (Row) Ltd Controlled release pharmaceutical composition of varenicline
EP4142734A1 (en) 2020-04-28 2023-03-08 Oyster Point Pharma, Inc. Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections
KR20240038022A (ko) 2021-08-20 2024-03-22 비위트 파마슈티컬 컴퍼니 리미티드 니트로사민 불순물, 니트로사민 불순물 생성을 줄일 수 있는 바레니클린 약학 조성물 및 그 제조와 응용
KR20230068877A (ko) 2021-11-11 2023-05-18 주식회사 아울바이오 고용량 바레니클린을 포함하는 미립구 및 이의 제조방법 및 이를 포함하는 약학적 조성물
CN113980020B (zh) * 2021-11-22 2023-05-09 浙江车头制药股份有限公司 一种酒石酸伐尼克兰晶型的制备方法
WO2023275413A2 (en) 2021-12-23 2023-01-05 Medichem, S.A. Solid pharmaceutical formulations of varenicline
EP4241775A1 (en) 2022-03-11 2023-09-13 Par Pharmaceutical, Inc. Tablet comprising varenicline and process of preparation thereof
US11602537B2 (en) 2022-03-11 2023-03-14 Par Pharmaceutical, Inc. Varenicline compound and process of manufacture thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3471503A (en) 1967-05-05 1969-10-07 Mcneilab Inc 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols
CN1715280A (zh) * 1997-12-31 2006-01-04 辉瑞产品公司 芳基稠合氮杂多环化合物
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic

Also Published As

Publication number Publication date
TWI262078B (en) 2006-09-21
GT200200084A (es) 2003-09-12
IL157933A0 (en) 2004-03-28
ME00466B (me) 2011-10-10
HRP20030910A2 (en) 2004-02-29
PA8545101A1 (es) 2003-09-05
NO20035036D0 (no) 2003-11-13
SK13362003A3 (en) 2004-11-03
BG66408B1 (bg) 2014-01-31
MY127807A (en) 2006-12-29
IS6957A (is) 2003-09-15
EE05441B1 (et) 2011-08-15
DE60205742D1 (de) 2005-09-29
EP1392307A1 (en) 2004-03-03
BR0209605A (pt) 2004-03-23
IS2217B (is) 2007-03-15
CZ304763B6 (cs) 2014-10-01
CA2447405C (en) 2006-10-17
EP1392307B1 (en) 2005-08-24
EE200300556A (et) 2004-04-15
CZ20032916A3 (cs) 2004-09-15
US20050148591A1 (en) 2005-07-07
HK1062645A1 (en) 2004-11-19
ZA200307235B (en) 2004-09-16
EA200301121A1 (ru) 2004-02-26
UA73422C2 (en) 2005-07-15
SI1392307T1 (sl) 2005-12-31
DOP2002000392A (es) 2002-11-15
BG108343A (bg) 2004-12-30
DE60205742T2 (de) 2006-05-11
HUP0304088A2 (hu) 2004-04-28
PE20021065A1 (es) 2002-11-21
ATE302607T1 (de) 2005-09-15
ES2246396T3 (es) 2006-02-16
NZ528210A (en) 2005-04-29
AR033635A1 (es) 2003-12-26
OA12599A (en) 2006-06-08
US20030166701A1 (en) 2003-09-04
HUP0304088A3 (en) 2011-11-28
MXPA03010364A (es) 2004-03-16
EG24228A (en) 2008-11-10
SK287170B6 (sk) 2010-02-08
AU2002253482B2 (en) 2007-09-06
HU229867B1 (en) 2014-10-28
HRP20030910B1 (en) 2011-11-30
GEP20053712B (en) 2005-12-26
NO326148B1 (no) 2008-10-06
JP2004533446A (ja) 2004-11-04
PL214876B1 (pl) 2013-09-30
AP2002002523A0 (en) 2002-06-30
KR20040010638A (ko) 2004-01-31
NO20035036L (no) 2003-11-13
PL366551A1 (en) 2005-02-07
US7265119B2 (en) 2007-09-04
EA005528B1 (ru) 2005-04-28
ECSP034849A (es) 2003-12-24
CN1509174A (zh) 2004-06-30
JP3779682B2 (ja) 2006-05-31
CR7080A (es) 2006-08-09
CA2447405A1 (en) 2002-11-21
CN100370987C (zh) 2008-02-27
DK1392307T3 (da) 2005-11-07
YU86703A (sh) 2006-05-25
IL157933A (en) 2013-07-31
WO2002092089A1 (en) 2002-11-21
MA27020A1 (fr) 2004-12-20
AP1473A (en) 2005-09-30
TNSN03113A1 (fr) 2005-12-23
US6890927B2 (en) 2005-05-10
RS50814B (sr) 2010-08-31
KR100551184B1 (ko) 2006-02-13
ECSP034850A (es) 2003-12-24

Similar Documents

Publication Publication Date Title
PT1392307E (pt) Sais tartarato de 5,8,14-triazatetraciclo-[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaeno
ZA200410015B (en) Pharmaceutical salts.
ATE356625T1 (de) Orale pharmazeutische zusammensetzungen mit verzögerter freisetzung enthaltend 5,8,14- triazatetracyclo (10.3.1.0(2,11) 0 (4,9) )- hexadeca-2(11) 3, 5,7, 9-pentaene
EE200300557A (et) 5,8,14-triasatetratsüklo [10,3,1,0 2,11 ,0 4,9]heksadeka-2(11),3,5,7,9-pentaeeni tsitraatsool
ES1049590Y (es) Cenicero ambientador perfeccionado.
ES1050018Y (es) Macetero perfeccionado.
ES1049608Y (es) Grifo de pulsador perfeccionado.
ITRM20010151V0 (it) Macchina trincia-erba perfezionata.
ES1048649Y (es) Cepillo de dientes perfeccionado.
ES1050042Y (es) Botellero perfeccionado.
ES1050374Y (es) Maquina pulidora perfeccionada.
ES1046870Y (es) Grifo perfeccionado.
ES1049820Y (es) Gafa perfeccionada.
ES1049575Y (es) Gafa perfeccionada.
ES1045547Y (es) Botellero perfeccionado.
ES1049836Y (es) Barandilla perfeccionada.
ES1045376Y (es) Embudo encauzador de persiana perfeccionado.
ES1050049Y (es) Prenda de vestir perfeccionada.
ES1045729Y (es) Enfriador de botellas perfeccionado.
ES1046982Y (es) Pelota de golf perfeccionada.
ES1046142Y (es) Disposicion de pulido perfeccionada.
ES1049809Y (es) Humidificador-fitosanitario perfeccionado.
ES1050515Y (es) Boligrafo perfeccionado.
ES1049053Y (es) Tenacillas perfeccionadas.
ES1049502Y (es) Cortina-mosquitera perfeccionada.